JP2011173813A - PPARα発現促進剤 - Google Patents
PPARα発現促進剤 Download PDFInfo
- Publication number
- JP2011173813A JP2011173813A JP2010037614A JP2010037614A JP2011173813A JP 2011173813 A JP2011173813 A JP 2011173813A JP 2010037614 A JP2010037614 A JP 2010037614A JP 2010037614 A JP2010037614 A JP 2010037614A JP 2011173813 A JP2011173813 A JP 2011173813A
- Authority
- JP
- Japan
- Prior art keywords
- glucosylceramide
- pparα
- expression
- expression promoter
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 78
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 title claims abstract description 66
- 102000023984 PPAR alpha Human genes 0.000 title claims abstract 8
- 150000002305 glucosylceramides Chemical class 0.000 claims abstract description 72
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 238000009825 accumulation Methods 0.000 claims abstract description 9
- 210000001596 intra-abdominal fat Anatomy 0.000 claims abstract description 9
- 240000008042 Zea mays Species 0.000 claims description 12
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 12
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 12
- 235000005822 corn Nutrition 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 72
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 63
- 102000012141 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- 238000011282 treatment Methods 0.000 description 46
- 238000001556 precipitation Methods 0.000 description 35
- 235000013305 food Nutrition 0.000 description 34
- 238000000034 method Methods 0.000 description 20
- 230000001737 promoting effect Effects 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 108010076365 Adiponectin Proteins 0.000 description 11
- 102000011690 Adiponectin Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000007796 conventional method Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 235000013373 food additive Nutrition 0.000 description 9
- 239000002778 food additive Substances 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- -1 ester lipids Chemical class 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 238000000105 evaporative light scattering detection Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 239000008177 pharmaceutical agent Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 6
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000419 plant extract Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 101150096417 Hmgcs1 gene Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 101100000438 Mus musculus Acacb gene Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 101150043789 cpt2 gene Proteins 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000004136 fatty acid synthesis Effects 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 229940125753 fibrate Drugs 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 2
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 2
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 2
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000020991 processed meat Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- 102000003808 Adiponectin Receptors Human genes 0.000 description 1
- 108090000179 Adiponectin Receptors Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- YBSQGNFRWZKFMJ-UHFFFAOYSA-N Cerebroside B Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O YBSQGNFRWZKFMJ-UHFFFAOYSA-N 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- OJFDKHTZOUZBOS-CITAKDKDSA-N acetoacetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OJFDKHTZOUZBOS-CITAKDKDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 230000001258 dyslipidemic effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 108700002051 rat Adipoq Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
【解決手段】本発明により、グルコシルセラミドを有効成分とするPPARα発現促進剤が提供される。当該PPARα発現促進剤は、特に内臓脂肪蓄積抑制効果、血中コレステロール値改善効果、インスリン感受性亢進効果に優れる。
【選択図】なし
Description
項1.
グルコシルセラミドを有効成分とする、PPARα発現促進剤。
項2.
トウモロコシ由来グルコシルセラミドを有効成分とする、項1に記載のPPARα発現促進剤。
項3.
内臓脂肪蓄積抑制剤である、項1又は2に記載のPPARα発現促進剤。
項4.
脂質異常症治療及び予防剤である、項1又は2に記載のPPARα発現促進剤。
コーン胚芽4kgにエタノール8Lを加え、1時間撹拌した後、ろ別して可溶部を回収した。そして、これをロータリーエバポレーターにより濃縮乾固した結果、抽出物が約480g得られた。これに常法に従い脱ガム処理を行い、80gのコーン由来粗グルコシルセラミド画分(脱ガム物)を得た。
コーン由来粗グルコシルセラミド画分72g(脱ガム物)に対し、アセトンを700mL加えて激しく撹拌し、遠心分離して沈殿を回収した。当該アセトン沈殿処理を5回繰り返した。さらに、アセトン沈殿処理にて得られた沈殿に対し、ヘキサン/アセトン(1:1)を350mL加えて激しく撹拌し、遠心分離して沈殿を回収した。当該ヘキサン及びアセトン沈殿処理を3回繰り返した。
コーン由来グルコシルセラミド画分にエタノール600mL(20mL/1g)を加え、撹拌し、遠心分離して上清を回収した。当該エタノール沈殿処理を2回繰り返し、得られた上清を全て合わせてグルコシルセラミド含有画分とした。当該画分をロータリーエバポレーターで濃縮乾固し、得られた固形物をヘキサンに溶解してチューブへ移し、さらに4倍容量のアセトンでアセトン沈殿処理を行って、沈殿(グルコシルセラミド)を18.4g得た。
上述のようにして得られたグルコシルセラミドを、クロロホルム/メタノール(2:1)液に溶解させ、HPLC−ELSDにより解析してクロマトグラムを得た。得られたクロマトグラムを図1に示す。上図にグルコシルセラミドが1.5μg含まれる溶液を解析した結果を、下図にグルコシルセラミドが10μg含まれる溶液を解析した結果を示す。なお、当該HPLC−ELSD解析の条件は以下の通りである。
検出方法:ELSD(蒸発光散乱検出)
分離:2液グラジエント
A液(溶出液):ヘキサン/イソプロパノール/酢酸(82:17:1)
B液(溶出液):イソプロパノール/水/酢酸/トリエチルアミン(85:14:1:0.2)
グルコシルセラミドを含有させた飼料を、肥満モデルラットに摂取させ、PPARα発現が促進されるか検討した。なお、以下で使用するグルコシルセラミドは、上述のようにして得たものである。
実験に使用するラットの飼料として、AIN-76(米国国立栄養研究所により1977年に発表された マウス・ラットを用いた栄養研究のための標準精製飼料組成:以下「通常飼料」と表記することがある)を購入した。また、特別注文により、グルコシルセラミドを0.1質量%含有するAIN-76、及びグルコシルセラミドを0.5質量%含有するAIN-76(以下それぞれ「0.1%GlcCer飼料」、「0.5%GlcCer飼料」と記載することがある)を購入した(いずれもオリエンタル酵母株式会社)。
肥満モデルであるZucker fa/faラット(Zucker-fattyラット)を日本エスエルシー株式会社から購入し、一週間の予備飼育後、コントロール群、0.1%群、及び0.5%群の3群に群分けした(いずれの群もn=6)。予備飼育は水及び通常飼料を自由摂取条件下で行った。群分け後は、コントロール群には通常飼料を、0.1%群には0.1%GlcCer飼料を、0.5%群には0.5%GlcCer飼料を、それぞれ摂取させ、6週間飼育した。なお、6週間飼育の間、水及び各飼料は自由摂取とした。
Cpt2:カルニチンに長鎖脂肪酸(アシルCoA)を結合させ、ミトコンドリア内膜に輸送するβ酸化系酵素の1種で、ミトコンドリア内膜内側に局在する。PPARαにより発現が亢進される。
Claims (4)
- グルコシルセラミドを有効成分とする、PPARα発現促進剤。
- トウモロコシ由来グルコシルセラミドを有効成分とする、請求項1に記載のPPARα発現促進剤。
- 内臓脂肪蓄積抑制剤である、請求項1又は2に記載のPPARα発現促進剤。
- 脂質異常症治療及び予防剤である、請求項1又は2に記載のPPARα発現促進剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010037614A JP2011173813A (ja) | 2010-02-23 | 2010-02-23 | PPARα発現促進剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010037614A JP2011173813A (ja) | 2010-02-23 | 2010-02-23 | PPARα発現促進剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2011173813A true JP2011173813A (ja) | 2011-09-08 |
Family
ID=44687041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010037614A Pending JP2011173813A (ja) | 2010-02-23 | 2010-02-23 | PPARα発現促進剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2011173813A (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016188180A (ja) * | 2015-03-30 | 2016-11-04 | 株式会社東洋新薬 | 特定成分含有組成物 |
JP2018070476A (ja) * | 2016-10-26 | 2018-05-10 | 株式会社ダイセル | ニューロピリン機能調節剤 |
JP2021054860A (ja) * | 2021-01-06 | 2021-04-08 | 株式会社ダイセル | ニューロピリン機能調節剤 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001527046A (ja) * | 1997-12-30 | 2001-12-25 | エイプラス サイエンス インベスト アーベー | ガラクトシルセラミド、グルコシルセラミド、ラクトシルセラミド、並びに前糖尿病、糖尿病および/または関連合併症の予防もしくは治療に使用するためのその特定キャッチャー |
JP2002275072A (ja) * | 2001-03-21 | 2002-09-25 | Snow Brand Milk Prod Co Ltd | 脂質代謝改善剤 |
JP2004256542A (ja) * | 2003-02-27 | 2004-09-16 | Enzo Therapeutics Inc | 中間代謝物質濃度の操作による免疫反応の調節 |
JP2006328041A (ja) * | 2005-04-25 | 2006-12-07 | Nippon Flour Mills Co Ltd | 抗腫瘍剤、腫瘍細胞増殖抑制剤、免疫賦活剤及び食品 |
JP2007135436A (ja) * | 2005-11-16 | 2007-06-07 | Nippon Flour Mills Co Ltd | グルコシルセラミド含有麺類 |
JP2007533632A (ja) * | 2003-09-30 | 2007-11-22 | エンゾー セラピューティクス, インコーポレイテッド | 疾患のグルコセレブロシド処理 |
JP2010064992A (ja) * | 2008-09-11 | 2010-03-25 | Hayashibara Biochem Lab Inc | ペルオキシソーム増殖剤応答性核内受容体α活性化剤 |
WO2011016558A1 (ja) * | 2009-08-06 | 2011-02-10 | 丸大食品株式会社 | グルコシルセラミド含有物の製造方法 |
-
2010
- 2010-02-23 JP JP2010037614A patent/JP2011173813A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001527046A (ja) * | 1997-12-30 | 2001-12-25 | エイプラス サイエンス インベスト アーベー | ガラクトシルセラミド、グルコシルセラミド、ラクトシルセラミド、並びに前糖尿病、糖尿病および/または関連合併症の予防もしくは治療に使用するためのその特定キャッチャー |
JP2002275072A (ja) * | 2001-03-21 | 2002-09-25 | Snow Brand Milk Prod Co Ltd | 脂質代謝改善剤 |
JP2004256542A (ja) * | 2003-02-27 | 2004-09-16 | Enzo Therapeutics Inc | 中間代謝物質濃度の操作による免疫反応の調節 |
JP2007533632A (ja) * | 2003-09-30 | 2007-11-22 | エンゾー セラピューティクス, インコーポレイテッド | 疾患のグルコセレブロシド処理 |
JP2006328041A (ja) * | 2005-04-25 | 2006-12-07 | Nippon Flour Mills Co Ltd | 抗腫瘍剤、腫瘍細胞増殖抑制剤、免疫賦活剤及び食品 |
JP2007135436A (ja) * | 2005-11-16 | 2007-06-07 | Nippon Flour Mills Co Ltd | グルコシルセラミド含有麺類 |
JP2010064992A (ja) * | 2008-09-11 | 2010-03-25 | Hayashibara Biochem Lab Inc | ペルオキシソーム増殖剤応答性核内受容体α活性化剤 |
WO2011016558A1 (ja) * | 2009-08-06 | 2011-02-10 | 丸大食品株式会社 | グルコシルセラミド含有物の製造方法 |
Non-Patent Citations (1)
Title |
---|
JPN6014012334; J.Biol.Chem. Vol.284, 2009, p.18942-18952 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016188180A (ja) * | 2015-03-30 | 2016-11-04 | 株式会社東洋新薬 | 特定成分含有組成物 |
JP2018070476A (ja) * | 2016-10-26 | 2018-05-10 | 株式会社ダイセル | ニューロピリン機能調節剤 |
JP2021054860A (ja) * | 2021-01-06 | 2021-04-08 | 株式会社ダイセル | ニューロピリン機能調節剤 |
JP7032771B2 (ja) | 2021-01-06 | 2022-03-09 | 株式会社ダイセル | ニューロピリン機能調節剤 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007029631A1 (ja) | 体内脂質改善組成物 | |
WO2013099982A1 (ja) | 筋萎縮抑制剤 | |
WO2009084275A1 (ja) | 経口投与組成物 | |
WO2011077800A1 (ja) | 高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品 | |
JP2008297209A (ja) | 脂質代謝改善組成物 | |
US8722614B2 (en) | Adiponectin production enhancer | |
JP2013071909A (ja) | 脳内過酸化脂質蓄積抑制剤 | |
JP2011173813A (ja) | PPARα発現促進剤 | |
JP3770628B2 (ja) | 遅延型アレルギー反応を介する医学的症状の予防及び改善剤 | |
JP2009137916A (ja) | 肥満改善用組成物 | |
JP5506229B2 (ja) | メタボリックシンドローム改善又は予防剤 | |
JP3616950B2 (ja) | 柑橘系由来の栄養組成物 | |
JP2007039386A (ja) | マーカータンパク質量調節用組成物、及びそれを含有する飲食品、飼料、医薬部外品、医薬品 | |
JP5122924B2 (ja) | 抗肥満剤 | |
JP2006335702A (ja) | アディポネクチン産生増強組成物 | |
JP2008088131A (ja) | 抗コレステロール組成物 | |
JP6770726B1 (ja) | メタボリックシンドロームの予防または改善剤 | |
JP2012206964A (ja) | PPAR−α活性調節剤 | |
JP5947061B2 (ja) | Srebp1抑制剤 | |
JP5577019B2 (ja) | 経口投与組成物 | |
JP2002255839A (ja) | 抗肥満剤 | |
JP2010105948A (ja) | 脂肪肝抑制剤 | |
JP2007246471A (ja) | 血中中性脂肪上昇抑制剤およびその製造方法 | |
JP5951512B2 (ja) | Cepathiolanesを有効成分とする脂質代謝改善用組成物、及び食品添加剤 | |
JP2001213782A (ja) | 大腸ガン予防剤及び予防食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130220 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140325 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140523 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141216 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150421 |